Corvus Pharmaceuticals Inc (NASDAQ:CRVS) CEO Richard A. Md Miller bought 100,000 shares of the firm’s stock in a transaction on Monday, March 12th. The stock was acquired at an average cost of $8.50 per share, with a total value of $850,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Corvus Pharmaceuticals Inc (CRVS) traded down $0.10 during trading on Monday, hitting $9.78. 76,111 shares of the stock were exchanged, compared to its average volume of 115,004. Corvus Pharmaceuticals Inc has a twelve month low of $7.42 and a twelve month high of $22.14.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, March 1st. The company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.18. research analysts anticipate that Corvus Pharmaceuticals Inc will post -3.15 EPS for the current fiscal year.
A number of brokerages have recently weighed in on CRVS. Cowen restated a “buy” rating on shares of Corvus Pharmaceuticals in a research note on Friday, March 2nd. Zacks Investment Research cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Finally, ValuEngine cut shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $20.25.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3257970/richard-a-md-miller-acquires-100000-shares-of-corvus-pharmaceuticals-inc-crvs-stock.html.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.